Roche Holding AG - ADR
RHHBY
Market Cap$263.51B
Close$
Earnings Call Q2 2024
July 25, 2024 - AI Summary
Group sales increased by 8% in the first half of the year, excluding COVID impact.
Pharma division saw strong growth in base business with an 8% increase in sales.
Diagnostics division also experienced solid growth with a 9% increase in sales.
Exclusive for Stockcircle Pro members
Sign up
$12.09
71.2% downside
Current Fair Value
71.2% downsideOvervalued by 71.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $263.51 Billion |
|---|---|
| Enterprise Value | $296.35 Billion |
| Dividend Yield | $1.36 (3.73%) |
| Earnings per Share | $1.3 |
| Beta | 0.17 |
| Outstanding Shares | 6,392,000,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 25.01 |
|---|---|
| PEG | -46.58 |
| Price to Sales | 2.62 |
| Price to Book Ratio | 8.39 |
| Enterprise Value to Revenue | 2.81 |
| Enterprise Value to EBIT | 13.24 |
| Enterprise Value to Net Income | 19 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | 1.25 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Roche Holding AG
CEO: Severin Schwan Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ...